← Back to Search

Platinum-based Compound

Combination Therapy for Brain Tumor

Phase 2
Waitlist Available
Led By Edward F. McClay, MD
Research Sponsored by San Diego Pacific Oncology & Hematology Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No acquired immune deficiency syndrome (AIDS)
ECOG performance status 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying radiation therapy in combination with temozolomide, tamoxifen, and carboplatin to treat patients with malignant gliomas.

Who is the study for?
This trial is for patients with specific brain tumors called malignant gliomas who've had surgery within the last 6 weeks. They should have a life expectancy over 12 weeks, be in good neurological and general health, not pregnant or nursing, and willing to use contraception. Those with major illnesses, prior head/neck radiotherapy, other cancers (except certain skin cancers or cervical carcinoma in situ), AIDS, or certain types of glioma are excluded.Check my eligibility
What is being tested?
The study tests if combining radiation therapy with chemotherapy drugs temozolomide and carboplatin plus tamoxifen (which may make tumor cells more sensitive) can better kill tumor cells in malignant glioma patients compared to current treatments.See study design
What are the potential side effects?
Potential side effects include typical reactions from radiation like fatigue and skin irritation; chemotherapy-related nausea, vomiting, hair loss; blood cell count changes leading to increased infection risk; and possible liver function alterations due to medication.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have AIDS.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I have been diagnosed with a specific type of brain tumor.
Select...
I can do most daily activities without help.
Select...
My bilirubin levels are not more than three times the upper limit.
Select...
My tumor is located above the cerebellum.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall survival
Progression-free survival
Toxicity
+1 more

Find a Location

Who is running the clinical trial?

San Diego Pacific Oncology & Hematology AssociatesLead Sponsor
3 Previous Clinical Trials
304 Total Patients Enrolled
Edward F. McClay, MDPrincipal InvestigatorSan Diego Pacific Oncology & Hematology Associates
3 Previous Clinical Trials
304 Total Patients Enrolled

Media Library

Carboplatin (Platinum-based Compound) Clinical Trial Eligibility Overview. Trial Name: NCT00492687 — Phase 2
Brain Tumor Research Study Groups:
Brain Tumor Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT00492687 — Phase 2
Carboplatin (Platinum-based Compound) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00492687 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can people with the target condition join this research project at this time?

"According to the information available on clinicaltrials.gov, this particular trial is not currently looking for patients. This trial was first posted on December 1st 2006 and was most recently updated on January 9th 2014. There are 444 other trials that are actively recruiting patients right now."

Answered by AI

What are the risks associated with this treatment option?

"This treatment received a safety score of 2 out of 3 because, while Phase 2 trials provide some evidence that the intervention is safe, there is no data yet supporting whether or not it is effective."

Answered by AI
~4 spots leftby Mar 2025